News and Press Releases
Press releases
Theralase® Closes $CAN 1.17 Million Non-Brokered Private Placement
November 29, 2023, Theralase® successfully closed a non-brokered private placement offering of units for gross proceeds of approximately $CAN...
0Theralase® Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Toronto, Ontario – November 17, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinic...
0Theralase® Announces Brokered LIFE Financing
Toronto, Ontario – October 23, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinica...
0Theralase® Provides Update on Bladder Cancer Clinical Study
Theralase®’s Latest Clinical Data Demonstrates 65% of Patients Treated with Theralase®’s Anti-Cancer Therapy Achieved a Complete Response Tor...
0Theralase® Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar™
Toronto, Ontario – September 29, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF) is a cli...
0Theralase® Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer
Toronto, Ontario – September 27, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF) is a cli...
0Theralase® Grants Stock Options
Toronto, Ontario – September 21, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clini...
0Theralase Release’s 2Q2023 Interim Financial Statements
Toronto, Ontario – August 29th, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clini...
0Theralase® Announces Appointment of New Independent Director
Toronto, Ontario – June 6, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical st...
0Theralase® Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements
In the Performance to Primary, Secondary and Tertiary Objectives second table the 90 day results were misstated and has been corrected in this pres...
0in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.